Table 3 New-onset neuropsychiatric symptoms frequency at the time of the follow-up phone call, 5–8 months after diagnosis, n (%) COVID phase (n = 236)
Phenotypes | Proportion, n (%) |
|---|---|
Neurologic outcomes | |
Memory complaint | 94 (39.8%) |
Concentration (sustained attention) complaint | 73 (30.9%) |
Daily activities disability | 43 (18.2%) |
Psychiatric and sleep complaints | |
Anxiety (GAD-2 score ≥ 3 points) | 87 (36.9%) |
Depression/sadness (most of the time) after COVID-19 | 100 (42.4%) |
Depression/sadness (most of the time) in the last 5 months | 95 (40.3%) |
Total depression (most of the time + in the last 5 months) | 106 (44.9%) |
Unsatisfied + very unsatisfied with sleep, n (%) | 83 (35.2%) |
Excessive daytime sleepiness | 57 (24.2%) |
Total sleep complaints: unsatisfied + very unsatisfied with sleep + excessive daytime sleepiness, n (%) | 108 (45.8%) |